|
|
T Schmitz, R Underwood, R Khiroya, W W Bachovchin, B T Huber
J Clin Invest. 1996;
97(6):1545
doi:10.1172/JCI118577
Abstract |
Full text
| PDF
T
cells from HIV-1+ individuals have a defect in mounting an antigen specific response. HIV-1 Tat has been implicated as the causative agent of this immunosuppression. We have previously shown that HIV-1 Tat inhibits antigen specific proliferation of normal T cells in vitro by binding to the accessory molecule CD26, a dipeptidase expressed on the surface of activated T cells. We now demonstrate that the defective in vitro recall antigen response in HIV-1 infected individuals can be restored by the addition of soluble CD26, probably by serving as a decoy receptor for HIV-1 Tat. The restored response is comparable to that of an HIV-1- individual, suggesting that early in HIV infection there is a block in the memory cell response, rather than deletion of these cells.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(7)
| Title and authors |
Publication |
Year |
Soluble CD26 / Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation In Vitro Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding
D. M. T. Yu, L. Slaitini, V. Gysbers, A. G. M. Riekhoff, T. Kähne, H. M. Knott, I. De Meester, C. A. Abbott, G. W. McCaughan, M. D. Gorrell
|
Scandinavian Journal of Immunology
|
2011 |
The dipeptidyl peptidase IV family in cancer and cell biology
Denise M. T. Yu, Tsun-Wen Yao, Sumaiya Chowdhury, Naveed A. Nadvi, Brenna Osborne, W. Bret Church, Geoffrey W. McCaughan, Mark D. Gorrell
|
FEBS Journal
|
2010 |
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
E.J. Verspohl
|
Pharmacology & Therapeutics
|
2009 |
An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy
N. M. Keane, P. Price, S. Lee, S. F. Stone, M. A. French
|
Clin Exp Immunol
|
2001 |
Decreased Dipeptidyl Peptidase IV Enzyme Activity of Plasma Soluble CD26 and Its Inverse Correlation with HIV-1 RNA in HIV-1 Infected Individuals
Osamu Hosono, Toshio Homma, Hiroshi Kobayashi, Yasuhiko Munakata, Yoshihisa Nojima, Aikichi Iwamoto, Chikao Morimoto
|
Clinical Immunology
|
1999 |
Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2
ZANUSSI, SIMONELLI, BORTOLIN, D'ANDREA, CREPALDI, VACCHER, NASTI, POLITI, BARZAN, TIRELLI, DE PAOLI
|
Clin Exp Immunol
|
1999 |
Dipeptidyl-Peptidase IV-beta, a Novel form of Cell-Surface-Expressed Protein with Dipeptidyl-Peptidase IV Activity
Etienne Jacotot, Christian Callebaut, Julia Blanco, Bernard Krust, Klaus Neubert, Alfred Barth, Ara G. Hovanessian
|
Eur J Biochem
|
1996 |
|